The role of the essential necroptosis effector, MLKL, in gastrointestinal tumorigenesis

Project Description

Colorectal cancer (CRC) is the second most common type of cancer in Australia. Unfortunately, only a small number of CRCs are detected in the early stages, and once CRC has spread to other parts of the body, current therapies are ineffective. We will use clinically relevant mouse models to define the contribution of necroptosis, a new programmed cell death pathway, to the initiation and progression of CRC. Our objective is to improve the development of new anti-cancer therapies for advanced CRC.

Lay report

Year

2015-2017

Researchers

Dr James Murphy, Dr Silvia Alvarez-Diaz, A/Prof Matthias Ernst

Funding Body

Cancer Council Research Grant

Institution

Cell Signalling and Cell Death, The Walter and Eliza Hall Institute of Medical Research

Funding

$99,826 per annum

Updated: